Edition:
United States

Chimerix Inc (CMRX.OQ)

CMRX.OQ on NASDAQ Stock Exchange Global Market

5.01USD
22 Sep 2017
Change (% chg)

$-0.02 (-0.40%)
Prev Close
$5.03
Open
$5.00
Day's High
$5.04
Day's Low
$4.95
Volume
65,446
Avg. Vol
60,871
52-wk High
$6.63
52-wk Low
$3.67

Chart for

About

Chimerix, Inc. is a biotechnology company. The Company is focused on discovering, developing and commercializing medicines that address unmet medical needs. Its lead compound, brincidofovir, is in development as an oral and intravenous (IV) formulation for the prevention and treatment of deoxyribonucleic acid (DNA) viruses,... (more)

Overall

Beta: 1.54
Market Cap(Mil.): $235.70
Shares Outstanding(Mil.): 47.05
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 81.40 16.08
EPS (TTM): -- -- --
ROI: -- 3.18 14.60
ROE: -- 4.93 14.03

BRIEF-Chimerix Inc appoints Heather Knight-Trent vice president of regulatory affairs

* Chimerix appoints Heather Knight-Trent, PHARMD, as vice president of regulatory affairs Source text for Eikon: Further company coverage:

Sep 12 2017

BRIEF-Chimerix reports Q2 loss per share $0.36

* Q2 earnings per share view $-0.41 -- Thomson Reuters I/B/E/S Source text for Eikon: Further company coverage:

Aug 07 2017

BRIEF-Chimerix Q1 loss per share $0.38

* Q1 earnings per share view $-0.36 -- Thomson Reuters I/B/E/S Source text for Eikon: Further company coverage:

May 09 2017

Competitors

Earnings vs. Estimates